INTERVIEW: What Does the FDA Advisory Peptide Vote Mean for Physicians and Patients?

In this interview with Impact Newswire, Dr. Gevork “JoJo” Tatarian, a Florida-based cosmetic surgeon and co-owner of Elevé Cosmetic Surgery, discusses the growing popularity of peptides, the implications of the U.S. Food and Drug Administration’s recent advisory panel vote on compounded peptides, and what the evolving regulatory landscape means for physicians and patients. As regulators determine the future of compounded peptides, the debate is increasingly about more than a single class of therapies. It reflects a broader challenge confronting modern medicine: how to balance scientific innovation with patient safety in an era when social media, online marketplaces and consumer demand often move much faster than clinical research and regulation. For physicians, the task is to separate evidence from marketing while helping patients navigate a rapidly evolving field. For patients, experts say the safest path remains working with qualified healthcare providers and relying on treatments supported by robust clinical evidence rather than online hype. 

Peptides have become one of the fastest-growing trends in wellness, anti-aging, sports recovery and aesthetic medicine, fueled by social media, fitness influencers and growing consumer demand for treatments that promise faster healing, improved performance and healthier aging. Yet many of these compounds have entered mainstream use despite limited clinical evidence and an evolving regulatory framework.

That debate has intensified after the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) voted on July 23 to recommend adding several widely used peptides, including BPC-157, to the list of substances that may be used by licensed compounding pharmacies under specific conditions. 

While the vote does not make the peptides FDA approved and is not binding on the agency, it marks an important step in determining how physicians may prescribe these therapies and how patients access them in the future.

The decision has reignited questions about peptide safety, clinical evidence, regulatory oversight and the growing gray market for injectable compounds sold online. It also highlights the widening gap between consumer demand and scientific research, as physicians increasingly navigate patient interest in therapies whose popularity has outpaced rigorous clinical testing.

To understand what the FDA advisory panel’s recommendation means for physicians, patients and the future of peptide medicine, Faustine Ngila spoke with Dr. Gevork “JoJo” Tatarian, a board-certified Florida cosmetic surgeon and co-owner of Elevé Cosmetic Surgery. Here is the interview excerpt:

1. What does the FDA advisory panel’s vote actually change for physicians and patients, and what misconceptions are you already seeing about its impact?

If the FDA ultimately accepts the committee’s recommendation, physicians may be able to prescribe certain peptide formulations through licensed 503A compounding pharmacies under specific legal conditions rather than watching patients turn to unregulated online sources. Compounding pharmacies would have clearer authority to prepare individualized prescriptions using these peptides, potentially moving some therapies out of today’s legal gray area.

For patients, however, the change is far more modest than many headlines suggest. The advisory vote is non-binding, and the FDA must still review the evidence, public comments, and internal analyses before issuing a final rule. Even if adopted, these peptides would not become FDA-approved drugs with standardized indications, dosing, or labeling. They would simply become ingredients that eligible compounding pharmacies may use when prescribed by a licensed clinician.

One misconception already circulating is that “BPC-157 is now FDA-approved.” That is incorrect. The committee did not approve BPC-157 as a drug; it recommended allowing it to be considered as a bulk substance for compounding under Section 503A. Another misconception is that the FDA has declared these peptides safe. In reality, FDA scientists expressed concerns about the limited human evidence and uncertain safety profiles. This vote is one step in a longer regulatory process—not an overnight change in clinical practice.

2. BPC-157 and similar peptides have exploded in popularity online despite limited human data. Why has demand outpaced the science?

Demand has been driven less by strong clinical evidence than by social media, podcasts, fitness culture, and the promise of faster healing and optimization. Patients are looking for solutions for tendon injuries, gut health, recovery, anti-aging, and overall wellness, often based on animal studies, mechanistic theories, and anecdotal success stories rather than rigorous human trials.

Therapeutic peptides are scientifically intriguing because they can be highly targeted and biologically potent. Many FDA-approved medications are peptide-based. However, there is a significant difference between well-studied peptide drugs, such as GLP-1 agonists, and many of the compounds currently promoted online. Investment in large clinical trials has lagged, allowing marketing to move much faster than the science.

3. Many consumers assume peptides are safe because they’re naturally occurring in the body. What do you make of that assumption?

It’s a common misconception, but it’s overly simplistic. While many peptides originate naturally in the body, isolating them, modifying them, and administering them at pharmacologic doses can dramatically change how they behave.

Natural origin does not automatically mean safe. Some peptides can influence blood pressure, immune function, coagulation, and other biological systems in ways that may be beneficial at one dose but harmful at another. FDA-approved peptide medications undergo extensive clinical testing and long-term safety monitoring. Many of the injectable peptides currently marketed online have little or no comparable human data, so their long-term safety remains unknown.

4. What are the biggest risks associated with buying peptides from online or unregulated sources instead of through licensed healthcare providers?

The greatest concern is quality control. Products purchased from unregulated sources may contain incorrect doses, contaminants, impurities, or even entirely different substances than what’s listed on the label.

Patients also face the risks of experimental dosing, since many online protocols are based on influencer recommendations rather than medical evidence. Self-injection with products of uncertain sterility increases the risk of infection, abscess formation, scarring, and systemic illness. In addition, some peptides remain prohibited or restricted by regulators and athletic organizations regardless of where they are obtained.

5. How should patients distinguish between evidence-based peptide therapies and products that are being marketed with exaggerated or unsupported claims?

Patients should start by evaluating the regulatory status of the product. Evidence-based peptide therapies are either FDA-approved for specific medical conditions or are being studied in legitimate clinical trials or prescribed through appropriate compounding pathways.

They should also look for high-quality human clinical data—not just animal studies or testimonials—and work with licensed healthcare professionals who provide appropriate evaluation, informed consent, and follow-up. Finally, patients should be skeptical of products claiming to treat numerous unrelated conditions simultaneously. Legitimate therapies are supported by specific evidence for specific indications.

6. What’s the difference between topical and injectable peptides in terms of safety, regulation, and the conditions they’re intended to treat?

Topical peptides used in skincare, such as signal peptides or copper peptides, are generally regulated as cosmetics when marketed solely to improve skin appearance. They have limited systemic absorption and generally carry relatively low risk beyond occasional skin irritation or allergy.

Injectable peptides are fundamentally different. They act more like drugs, entering the body to influence healing, metabolism, hormones, or immune function. Because of that, they require sterile manufacturing, precise dosing, and substantially stronger safety data. Many injectable peptides currently promoted for wellness or recovery have not undergone the rigorous clinical trials typically expected before widespread medical use.

7. Do you expect the FDA panel’s recommendation to reduce reliance on the gray market, or could it inadvertently fuel even greater demand for peptides?

Potentially both. Allowing physicians to prescribe certain compounded peptides could gradually move some patients away from unregulated online sellers and into licensed medical settings with better oversight and quality control.

At the same time, headlines suggesting that restrictions are being eased may be misunderstood as broad FDA approval. That misunderstanding could unintentionally increase demand, particularly if gray-market vendors use the advisory vote as a marketing tool. Clear communication from regulators and healthcare professionals will be essential.

8. What additional clinical evidence or regulatory safeguards are needed before peptides become part of mainstream medical practice?

Several important steps remain. We need large, well-designed randomized clinical trials evaluating individual peptides for specific medical conditions using standardized dosing and meaningful long-term outcomes. We also need stronger safety data, including information on pharmacokinetics, drug interactions, immune effects, and long-term risks.

Equally important are consistent GMP manufacturing standards, independent quality testing, transparent labeling, and clear regulatory guidance for clinicians and compounding pharmacies.

Peptide science is promising, but enthusiasm has outpaced the evidence. Until stronger clinical data and clearer regulatory guidance are available, patients should avoid self-injecting unregulated products purchased online and instead seek guidance from qualified healthcare professionals.

Stay ahead of the stories shaping our world. Subscribe to Impact Newswire for timely, curated insights on global tech, business, and innovation all in one place.

Dive deeper into the future with the Cause Effect 4.0 Podcast, where we explore the ideas, trends, and technologies driving the global AI conversation.

Got a story to share? Pitch it to us at info@impactnews-wire.com and reach the right audience worldwide